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Background: When discontinuation in COPD randomized controlled trials (RCTs) is unevenly 
distributed between treatments (differential dropout), the capacity to demonstrate treatment 
effects may be reduced. We investigated the impact of the time of differential dropout on 
exacerbation outcomes in RCTs, in relation to study duration and COPD severity.
Methods: A post hoc analysis of 2,345 patients from three RCTs of 6- and 12-month duration 
was performed to compare budesonide/formoterol and formoterol in moderate, severe, and very 
severe COPD. Outcomes were exacerbation rate, time-to-first exacerbation, or discontinuation; 
patients were stratified by disease severity. Outcomes were studied by censoring data monthly 
from 1 to 12 months.
Results: In patients treated with budesonide/formoterol, annualized exacerbation rates (AERs) 
were comparable for each study duration (rate ratio [RR] =0.6). With formoterol, the AER 
decreased with study duration (RR =1.20 at 1 month to RR =0.86 at 12 months). There was a treat-
ment-related difference in exacerbation rates of 45%–48% for shorter study durations (#4 months) 
and 27% for 12-month duration. This treatment-related difference in exacerbation rates was 
comparable for the three disease severities in studies #4 months (range: 39%–51%), but this 
difference decreased with longer study durations, especially in more severe groups (22% and 29% 
at 12 months). There were fewer discontinuations with budesonide/formoterol; the treatment-
related difference in time-to-first discontinuation decreased by study duration (35%, 30%, 26%, 
and 22% at 3, 6, 9, and 12 months, respectively). Numbers of differential dropouts increased with 
increasing disease severity, being greatest during second, third, and fourth months.
Conclusions: COPD severity and study duration impact exacerbation as an outcome in 
double-blind RCTs. This effect is most obvious in patients with severe/very severe COPD and 
in studies that are longer than 4 months. Early differential dropout particularly impacts study 
outcome, producing a “healthy survivor effect,” which reduces estimations of treatment impact 
on exacerbations.
Keywords: healthy survivor effect, exacerbation outcomes, early differential dropout, RCT, 
disease severity
Background
In patients with COPD, double-blind, randomized controlled trials (RCTs) conducted 
over 6–12 months are regarded as the most rigorous way to evaluate the efficacy of 
treatments for symptomatic benefit and/or prevention of future risks, such as exacer-
bations.1 These trials often show significant treatment effects compared with placebo, 
but differences between active treatment arms may only be seen when data are pooled 
or larger studies conducted.2–4 A consistent finding in RCTs in COPD patients is a high 
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rate of discontinuation, ranging from 27% to 53%,5 espe-
cially among those with more severe disease. Furthermore, 
discontinuation occurs early in a trial6,7 and correlates with 
disease severity.8 This should not cause a major problem 
when interpreting RCTs, provided that discontinuation is 
a random phenomenon between the interventions studied. 
However, the power calculation for the primary variable 
needs to compensate for this effect, as the loss of information 
over time may impact the ability of the study to confidently 
identify or exclude a treatment effect. A particular problem 
arises when differential dropout between study arms occurs 
on top of evenly distributed random discontinuations. The net 
effect can lead to potential bias in favor of a weaker treatment, 
if the sicker people in that arm are lost during follow-up.9
In this report, we investigate the impact of both disease 
severity and study duration on COPD exacerbations in 
double-blind RCTs. A secondary objective was to better 
understand the impact of premature discontinuations, on 
exacerbation frequency and treatment effect in relation to dis-
ease severity and study duration. A large data set from three 
RCTs10–12 was interrogated as the basis for these analyses.
Methods
study design and patient population
We analyzed data from three double-blind, randomized, 
double-dummy, parallel-group, placebo-controlled, 
multicenter clinical trials of 6 (NCT0020615412) and 
12 months duration (NCT0020616710 and NCT0041974411). 
The efficacy of budesonide/formoterol 320/9 µg and for-
moterol 9 µg (two inhalations twice daily) (AstraZeneca, 
Mölndal, Sweden) was compared in patients with COPD. 
Salbutamol (albuterol) was allowed as reliever medication 
during screening, run-in, and throughout all studies. All 
studies were conducted in accordance with the Declaration 
of Helsinki, Good Clinical Practice guidelines, and applicable 
regulatory requirements; all patients gave written, informed 
consent. These previously published trials were conducted in 
237 sites in the USA, Europe, and Mexico;10 180 sites in the 
USA, Central and South America, and South Africa;11 and 
194 centers in the USA, Czech Republic, the Netherlands, 
Poland, and South Africa.12 Ethical approval was provided 
in all countries by local Independent Ethics Committees at 
the time when the studies were first conducted, and details 
have previously been published.10–12
The study inclusion criteria were similar: smokers or 
ex-smokers with a smoking history of $10 pack-years; 
pre-bronchodilator forced expiratory volume in 1 second 
(FEV
1
) #50% predicted; pre-bronchodilator FEV
1
/forced 
vital capacity (FVC) ratio ,70%; age $40 years; COPD 
with a history of $1 COPD exacerbation requiring treatment 
with a course of systemic corticosteroids, antibiotics, or both 
1–12 months prior to screening; and a modified Medical 
Research Council dyspnea score of $2.
COPD severity and study duration
The impact of disease severity on exacerbation and dropout 
was assessed by stratifying patients by lung function – mod-
erate, severe, and very severe – according to GOLD recom-
mended criteria.13 Study duration was evaluated by censoring 
data after 1, 2, 3 months, etc., up to 12 months, thereby 
generating 12 subanalyses of increasing duration.
exacerbation as an endpoint
Our primary outcome was the impact of study duration and 
disease severity on exacerbations. A COPD exacerbation was 
defined as a worsening of COPD symptoms requiring treat-
ment with oral corticosteroids and/or hospitalization. Exacer-
bations were recorded by patients in diary cards and confirmed 
at a clinic visit by study investigators/coordinators.
Discontinuation as an endpoint
All discontinuations, irrespective of the reason, were sum-
marized by treatment. Individual reasons for discontinuations 
were also assessed for each treatment: failure to fulfill eligibility 
criteria, adverse event, withdrawal of consent (voluntary dis-
continuation by patient), lost to follow-up, and others.
exploratory endpoints
We investigated at which month(s) of follow-up the differ-
ential dropout peaked by conditional probability of dropout 
(CPDo), that is, the number of discontinuations in a month 
divided by the number of patients entering the defined month. 
A composite of exacerbation and discontinuation (ExDo) 
was created to evaluate whether early discontinuation could 
compensate for the loss of treatment effect on exacerbations 
over time due to early differential dropout.
statistical analyses
Analyses were performed for the overall patient population 
and the COPD severity subgroups – moderate, severe, and 
very severe. The impact of study duration was analyzed cumu-
latively for 0–1, 0–2, 0–3, etc., up to 0–12 months of duration, 
that is, data after the defined study duration were censored. 
As one trial12 had shorter study duration, these data were cen-
sored at 6 months. Differences in rates were analyzed using 
Poisson regression with study as a factor. Time-to-first events 
(exacerbation, discontinuations, and ExDo) were analyzed 
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using Cox-regression analysis with study as a factor. Rate 
ratios (RRs) and hazard ratios (HRs) with 95% confidence 
intervals and P-values were provided. Treatment-related dif-
ferences (RR and HR) were expressed as percentage reduction 
in exacerbations. CPDo was summarized descriptively up to 
6 months. Analyses used standard statistical software (SAS 
v9.2; SAS Institute, Inc., Cary, NC, USA).
Results
Demographics and baseline 
characteristics
Overall, 2,345 COPD patients (mean age: 63 years; 
63% male) were included in the analysis. Demographics and 
baseline characteristics for all patients, according to disease 
severity, are shown in Table 1. Studies included (mean) 17% 
moderate, 57% severe, and 26% very severe COPD patients 
according to GOLD FEV
1
 severity stage (Table 1).
effect of study duration and disease 
severity on exacerbation
exacerbations in all patients
Exacerbation rates per treatment were higher with longer 
study duration and more so with formoterol (RR =0.86 at 
12 months) than with budesonide/formoterol (RR =0.63 at 
12 months) (Figure 1A).
annualized exacerbation rates (aers) per treatment
In patients treated with budesonide/formoterol, the AERs for 
each study duration period were comparable irrespective of 
study duration (RR ≈0.6 exacerbation per patient and year). 
In the formoterol arm, the AER decreased from RR =1.20 
to RR =0.86 (a 28% reduction) over the 12-month period 
(Figure 1B; Table S1).
relative treatment difference in exacerbation rate
The differences between treatments in the exacerbation 
rates decreased with longer study duration. The reduction in 
favor of budesonide/formoterol was 45%–48% for shorter 
study durations (#4 months) and 27% for a study duration 
of 12 months (Figure 1C; Table S2).
Relative treatment difference in time-to-first 
exacerbation
The reductions in the risk of a first exacerbation between 
treatments were 40%–47% for shorter study durations 
(#4 months). Thereafter, the difference between treatments 
in time-to-first exacerbation decreased to 21% at 12 months 
(Figure 1D; Table S3).
exacerbations in moderate, severe, and very 
severe COPD
Exacerbation rates per treatment were higher in more severe 
patients and more so with formoterol (RR =0.64, RR =0.81, 
and RR =1.17 exacerbations per patient and 12 months for 
moderate, severe, and very severe, respectively) than with 
budesonide/formoterol (RR =0.39, RR =0.57, and RR =0.91, 
respectively) (Figure S1).
aers per treatment
In patients treated with budesonide/formoterol, the AERs did 
not change over time for the three severity groups, though 
the RR levels differed with disease severity (RR ≈0.45, 
RR ≈0.55, and RR ≈0.90 exacerbations per patient and 
year for moderate, severe, and very severe, respectively). 
In patients treated with formoterol, the AERs decreased 
over time and more so for more severe disease. The RRs 
for decrease in AERs from 1–12 months were 0.84–0.64 
Table 1 Demographic and baseline characteristics for all patients, stratified according to COPD disease severity group, treated with 
budesonide/formoterol or formoterol10–12
Characteristics All patients, 
n=2,345
COPD disease severity
Moderate, n=408 Severe, n=1,325 Very severe, n=612
age, years 63.2 (9.22) 61.6 (9.82) 63.6 (9.21) 63.4 (8.71)
Male, n (%) 1,487 (63) 206 (50) 833 (63) 448 (73)
FeV1 pre-BD, l 1.01 (0.41) 1.38 (0.43) 1.05 (0.33) 0.69 (0.26)
FeV1 post-BD, % predicted
a (range) 38.4 (10.0–103.1) 55.2 (50.0–103.1) 39.8 (30.0–50.0) 24.9 (10.0–30.0)
FeV1/FVC, ratio
a (range) 0.47 (0.15–0.97) 0.56 (0.28–0.91) 0.47 (0.19–0.98) 0.38 (0.15–0.93)
Pack-yearsa (range) 42.0 (10.0–258.0) 40.0 (10.0–168.0) 41.0 (10.0–258.0) 45.0 (10.0–184.0)
sgrQ total score 55.8 (16.9) 52.7 (16.8) 55.2 (17.3) 59.4 (15.6)
reliever use, inhalations/day 4.5 (4.0) 3.6 (3.2) 4.2 (3.7) 5.8 (4.7)
Notes: Data are presented as arithmetic mean (sD) unless otherwise stated. aThere were two patients with moderate COPD and one with severe COPD, who did not have 
an FeV1/FVC ,70% at run-in or randomization. Data from rennard et al;
10 sharafkhaneh et al;11 Tashkin et al.12
Abbreviations: BD, bronchodilator; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; sD, standard deviation; sgrQ, st george’s respiratory 
Questionnaire.
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(reduction of 23.8%), 1.10–0.81 (26.4%), and 1.68–1.17 
(30.4%) for moderate, severe, and very severe COPD, 
respectively (Table 2).
relative treatment difference in exacerbation rate
The exacerbation rate reduction of budesonide/formoterol 
versus formoterol over the first 4 months was similar across 
studies in moderate, severe, and very severe patients, 
ranging between 39% and 51% (Figure 2A; Table S2). 
In patients with moderate COPD, the initial difference in 
exacerbation rates (39%–50%) was generally maintained 
for all study durations up to 12 months. However, in the 
severe and very severe COPD groups, the initial effect 
(ranging between 41% and 51%) decreased to 29% and 
22% at 12 months, respectively.
Relative treatment difference in time-to-first 
exacerbation
Differences in time-to-first exacerbation between treat-
ments were similar for moderate, severe, and very severe 
disease when study duration was short (#4 months), ranging 
from 38% to 49% (Figure 2B). Thereafter, the differences 
decreased for all three disease severities, with a trend for 
greater decrease in difference with increasing disease severity 
(-25% [P=0.14], -23% [P,0.01], and -18% [P=0.12]) for 
moderate, severe, and very severe, respectively (Table S3).
Discontinuation and differential dropout
all discontinuations per study and treatment
The percentage of discontinuations was lower for budesonide/ 
formoterol than for formoterol alone. The difference in favor 
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Figure 1 exacerbations in all patients: (A) exacerbation rates for budesonide/formoterol and formoterol; (B) annualized exacerbation rates for budesonide/formoterol and 
formoterol; (C) percentage reduction in the exacerbation rates; (D) percentage reduction in time-to-first exacerbation.
Notes: Data in (A) and (B) are presented as estimated exacerbation rates with 95% confidence intervals. Data in (C) and (D) are presented as difference in estimated 
exacerbation rates with 95% confidence intervals in percentage.
Abbreviation: CI, confidence interval.
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of the budesonide/formoterol was 4.2% and 4.7% units in 
the two 12-month studies and 7.4% units in the 6-month 
study (Table 3).
reason for discontinuations per treatment
Adverse event and withdrawal of consent were the two domi-
nating reasons for discontinuations and differential dropout. 
More patients discontinued on formoterol than budesonide/
formoterol due to adverse events (2.4% units) and withdrawal 
of consent (2.0% units) (Table 4).
CPDo
Discontinuations were higher for formoterol-treated 
patients than for budesonide/formoterol-treated patients 
Table 2 annualized exacerbation rates for budesonide/formoterol and formoterol according to COPD disease severity group
Study 
month
Annualized exacerbation rates
Disease severity
Moderate, n=408 Severe, n=1,325 Very severe, n=612
BUD/
FOR
95% CI FOR 95% CI BUD/
FOR
95% CI FOR 95% CI BUD/
FOR
95% CI FOR 95% CI
1 0.48 0.24–0.84 0.84 0.48–1.44 0.60 0.39–0.72 1.08 0.84–1.32 0.96 0.6–1.32 1.68 1.2–2.28
2 0.48 0.30–0.78 0.78 0.54–1.08 0.54 0.42–0.66 1.08 0.90–1.26 0.90 0.66–1.2 1.74 1.38–2.16
3 0.44 0.32–0.68 0.84 0.60–1.12 0.52 0.44–0.64 1.04 0.92–1.24 0.88 0.68–1.12 1.48 1.20–1.76
4 0.45 0.33–0.66 0.84 0.63–1.08 0.54 0.45–0.66 0.99 0.87–1.14 0.84 0.66–1.05 1.53 1.29–1.80
5 0.43 0.31–0.60 0.82 0.65–1.06 0.60 0.50–0.70 0.98 0.86–1.10 0.86 0.72–1.06 1.44 1.22–1.68
6 0.44 0.34–0.62 0.78 0.78–0.98 0.60 0.52–0.70 0.96 0.86–1.08 0.96 0.82–1.14 1.44 1.24–1.66
7 0.43 0.32–0.58 0.74 0.58–0.91 0.62 0.53–0.70 0.93 0.82–1.03 0.98 0.84–1.15 1.34 1.33–1.52
8 0.42 0.33–0.57 0.71 0.57–0.87 0.62 0.54–0.69 0.89 0.80–0.99 0.98 0.84–1.13 1.26 1.10–1.44
9 0.43 0.32–0.56 0.69 0.57–0.85 0.63 0.55–0.70 0.88 0.80–0.98 0.97 0.84–1.12 1.24 1.09–1.41
10 0.41 0.31–0.53 0.72 0.59–0.88 0.61 0.54–0.68 0.86 0.80–0.96 0.95 0.83–1.1 1.24 1.08–1.40
11 0.40 0.30–0.52 0.64 0.57–0.84 0.66 0.55–0.68 0.84 0.83–0.93 0.93 0.81–1.07 1.21 1.07–1.37
12 0.39 0.30–0.50 0.64 0.53–0.78 0.57 0.51–0.64 0.81 0.73–0.89 0.91 0.80–1.04 1.17 1.03–1.32
Note: Data are presented as annualized exacerbation rates with 95% confidence intervals.
Abbreviations: BUD, budesonide; FOR, formoterol; CI, confidence interval.
? ? ? ? ? ? ? ? ? ?? ?? ???
???
???
???
???
????
????
????
??????
????????
???
???
????
???
????
????
???
????
?? ??? ? ? ? ? ? ? ? ? ???
???
???
???
???
????
????
???? ????????
??????
???
???
????
????
????
??
????
???
???
????
????
??
???
???
????
????
???
????
?
????
???
????
???
? ? ? ? ? ? ? ? ? ?? ?? ???
???
???
???
???
????
????
????
??????
??????
???
???
????
???
????
????
???
????
? ? ? ? ? ? ? ? ? ?? ?? ???
???
???
???
???
????
????
????
??????
???????
????
????
????
???
????
????
???
???
????
????
??
???
???
????
????
???
????
?
????
???
????
???
? ? ? ? ? ? ? ? ? ?? ?? ???
???
???
???
???
????
????
????
??????
???????????
???
???
????
???
????
????
???
????
? ? ? ? ? ? ? ? ?
??????
????????????
????
????
????
???
????
????
???
???
????
????
??
???
???
????
????
???
????
?
????
???
????
???
?
???
???
???
???
????
????
????
?? ?? ??
?
?
Figure 2 exacerbations over time in patients with moderate, severe, and very severe COPD: (A) treatment effect on exacerbation rate (% change in favor of budesonide/
formoterol over formoterol only) for different study durations; (B) risk reduction of time-to-first exacerbation (percentage change in favor of budesonide/formoterol over 
formoterol only) for different study durations.
Note: Data are presented with 95% confidence intervals.
Abbreviation: CI, confidence interval.
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at months 2, 3, and 4, and increased with disease severity 
(Figure 3). The pattern in moderate disease was not clear, 
since the number of discontinuations was the lowest and the 
cohort was the smallest.
Overall, this descriptive analysis indicated that the highest 
differential dropout occurred at months 2, 3, and 4.
Discontinuations
In all patients, the time-to-discontinuation was significantly 
shorter with formoterol than with budesonide/formoterol 
from 2 to 12 months. This treatment difference decreased 
with study duration (35%, 30%, 26%, and 22% at 3, 6, 
9, and 12 months, respectively). We observed a similar 
pattern with moderate and severe COPD, moving from treat-
ment differences of 32% and 34% at 3 months to 15% at 
12 months. In patients with moderate disease, no significant 
difference between treatments could be detected, whereas 
in patients with severe COPD, there was a statistically 
significant difference in time-to-first discontinuation at 3-, 
4-, 5-, and 6-month study durations in favor of the budes-
onide/formoterol group. The very severe group showed, 
however, significant treatment difference from 3 to 12 
months. This treatment difference was high over the whole 
study duration (34%–38% from 3 to 12 months) (Figure 4; 
Table S4).
Composite of exDo
ExDo, the composite of exacerbations and discontinuations, 
increased the number of events over that of exacerbations 
alone, both in all patients and in all three severity groups. 
ExDo also showed more consistent results in more severe 
COPD, where the differential dropout was more prominent. 
For example, the relative treatment difference in time-to-
exacerbation was 18%–19% and not significant in analyses 
of 7- to 12-month study durations, whereas relative treatment 
difference in time-to-ExDo was significant for all these study 
durations with a 21%–23% difference in favor of budesonide/
formoterol (Table 5).
Discussion
Our results demonstrate that both disease severity and study 
duration influence exacerbation outcomes in double-blind 
RCTs in COPD. This effect is particularly apparent in patients 
with severe/very severe COPD and in studies that are longer 
than 4 months’ duration, where early differential dropout 
resulted in a “healthy survivor effect”. This effect changed 
the composition of the study groups and tended to reduce 
the effect of therapy over time.
The impact of differential dropout on long-term effi-
cacy outcomes in COPD has been recognized as a potential 
source of bias, and several studies have highlighted this 
problem.7,8,14,15 These studies had all a follow-up of 3–4 years. 
However, the consequences for shorter term studies 
(#12 months), a commonly used study design in phases II–III 
and for regulatory purposes, has not been formally investi-
gated. This retrospective analysis of moderate-to-very-severe 
COPD in three RCTs10–12 of 6–12 months’ duration showed 
over time a marked loss in exacerbation difference between 
the two treatments: budesonide/formoterol and formoterol. 
This loss of treatment difference was increased by study dura-
tion and in more severe COPD, but these effects were almost 
negligible in moderate COPD. Of importance, the time-to-
first exacerbation was more impacted than exacerbation rates, 
Table 3 all discontinuations and differential dropouts by study 
and treatment arm
Treatment Randomized 
(N)
Discontinuations 
(N)
Discontinuations/
randomized (%)
BUD/FOra 494 134 27.1
BUD/FOrb 407 117 28.7
BUD/FOrc,d 277 39 14.1
FOra 495 157 31.7
FOrb 404 133 32.9
FOrc,d 284 61 21.5
Notes: Data from arennard et al;10 bsharafkhaneh et al;11 cTashkin et al;12 d6-month 
study.
Abbreviations: BUD, budesonide; FOr, formoterol.
Table 4 reasons for discontinuations per treatment arm
Reason for 
discontinuation
BUD/FOR (N) BUD/FOR, reason/
randomized (%)
FOR (N) FOR, reason/
randomized (%)
∆BUD/FOR–FOR (%)
adverse events 120 10.2 149 12.6 -2.4
Consent withdrawn 92 7.8 116 9.8 -2.0
Others 40 3.4 41 3.5 -0.1
eligibility 17 1.4 26 2.2 -0.8
lost to follow-up 21 1.8 19 1.6 +0.2
Total 290 24.6 351 29.7 -5.1
Note: ΔBUD/FOr–FOr, percentage unit difference for BUD/FOr–FOr. 
Abbreviations: BUD, budesonide; FOr, formoterol.
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and the differential dropout preceded the loss of treatment 
effect on exacerbations. We believe these results will further 
raise the awareness of how important study methodology, 
selection of patients, and calculation of sample size are in 
exacerbation studies.
In the budesonide/formoterol treatment arm, the AERs 
were similar for shorter and longer study durations, whereas 
they decreased over time with monotherapy formoterol, 
indicating differential effects of these treatments. Our 
shorter term data support those of Vestbo et al,7 reporting 
that differential withdrawal over a 3-year period resulted in 
a reduction in AERs from 6.8 to 0.9 in placebo and from 
3.0 to 0.8 with salmeterol/fluticasone. These data together, 
showing a decrease in AERs over time, indicate that weaker 
treatments may lose more patients over time, who are more 
exacerbation prone than those in the more active compara-
tor arm. We demonstrate that this effect can already be seen 
during the first 6 months in very severe patients.
The analyses of the relative treatment difference in 
exacerbation rate also demonstrate this time-dependent 
effect. In the whole population, this was already evident 
after .4 months’ study duration. A 45%–48% difference 
in studies of short duration was reduced to 27%–29% in the 
studies over 9–12 months. The time-to-first exacerbation 
analyses showed similar results, with a treatment differ-
ence being 40%–47% in the first 3 months, decreasing to 
21%–22% in months 9–12. The most likely explanation for 
the decrease in relative treatment difference is that the more 
severe patients randomized to formoterol are more vulnerable 
to early discontinuation than similarly severe patients in the 
budesonide/formoterol arm. These data may also explain why 
a 3-month study by Welte et al16 could show a 60% treatment 
difference between budesonide/formoterol and placebo and 
importantly with no differential dropout.
The impact of COPD severity on exacerbation outcomes 
has been investigated in many studies, but two studies 
specifically addressed the moderate, severe, and very 
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Figure 3 Discontinuations for budesonide/formoterol and formoterol in all patients, and difference in discontinuations for budesonide/formoterol versus formoterol in 
patients with moderate, severe, and very severe COPD.
Note: no data are presented after 6 months as the number of patients that drop out (one study 6 months) and the number of discontinuations per month decrease.
Abbreviations: BUD/FOr, budesonide/formoterol; FOr, formoterol.
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Figure 4 Percentage reduction in time to discontinuation for budesonide/formoterol 
compared with formoterol according to COPD disease severity.
Notes: Data are presented with 95% confidence intervals. Four discontinuations 
(three on formoterol and one on budesonide/formoterol) at 1 month in patients 
with moderate COPD.
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severe COPD subgroups.15,17 Our approach extends their 
work by showing that the impact on exacerbations occurs 
early (#12 months). In the three severity groups, we found 
that the AERs for the two treatments were consistent with 
those from the whole group, that is, budesonide/formoterol 
showed constant values over time irrespective of severity, 
whereas formoterol treatment was accompanied by a 
reduction in annualized exacerbations over time and with 
increased severity. As a consequence, the treatment differ-
ences with respect to the exacerbation rate decreased over 
time and with severity. These data support the assumption 
that more severe and unstable patients discontinue earlier 
in a treatment arm, where efficacy is not sufficient for the 
severity stage. The severity of COPD had less (or minimal) 
impact on studies with shorter duration (#4 months), while 
it was marked in studies beyond 5–6 months, and in studies 
involving patients with severe and very severe COPD. For 
these patients, the treatment effect decreased over time, 
from 41%–51% for shorter durations to 29% and 22%, 
respectively, at 12 months’ duration. However, the treatment 
difference in moderate disease remained unaffected over 
time (about 40%–45% difference in favor of budesonide/
formoterol). The results from the time-to-first exacerbation 
in the three severity groups paralleled our findings from the 
whole group. However, this statistical method seemed to be 
less powerful and sensitive to disease severity than using 
exacerbation rates. For example, the moderate severity group 
showed loss in effect over time for time-to-first exacerbation 
(but not with exacerbation rate) and the very severe group 
showed an initial significant difference in effect, whereas the 
effect was nonsignificant in study durations of 6–12 months 
(but not with exacerbation rate). Similar findings with 
time-to-first exacerbation analyses have been observed in 
corticosteroid withdrawal studies18 and may reflect a greater 
likelihood of frequent exacerbators to drop out early.
As expected, discontinuations in COPD studies were high, 
especially as our patients predominantly had severe-to-very-
severe COPD. We also found a higher discontinuation in 
the formoterol group, likely related to more treatment fail-
ures and/or more long-acting beta agonist (LABA)-related 
adverse events in the LABA-only group. As both groups used 
LABA and general adverse events were similar, it can be 
speculated that the differential dropout is related to a weaker 
effect of LABA alone. Two explanations predominated as 
causes of differential dropout: adverse event and withdrawal 
of informed consent. Both may be due to disease worsening 
or perceived lack of benefit. By comparison, reasons such 
as eligibility for the study, loss to follow-up, and “others” 
were more comparable between treatments.
To understand the time course of the differential drop-
out, we performed an exploratory analysis, investigating 
conditional probability to dropout (CPDo) at a certain 
month. The all-patient analysis showed that fewer patients 
discontinued during months 2, 3, and 4 on budesonide/
formoterol compared with formoterol alone. In the very 
severe group, a clear difference in discontinuation frequency 
was seen during months 2–5. Though the group with moder-
ate COPD also indicated a difference, the lower number of 
discontinuations due to less severe disease and longer time 
in the study made interpretation difficult.
Table 5 Time-to-exDo analyses for budesonide/formoterol versus formoterol in all patients and according to COPD disease severity 
group
Study 
month
Time-to-ExDo
All patients, n=2,345 Disease severity
P-value Moderate, n=408 Severe, n=1,325 Very severe, n=612
1 0.570 (0.429, 0.759) 0.0001 0.514 (0.220, 1.202) 0.589 (0.395, 0.879)* 0.558 (0.350, 0.889)*
2 0.571 (0.468, 0.697) ,0.0001 0.690 (0.385, 1.236) 0.552 (0.417, 0.731)*** 0.551 (0.398, 0.764)**
3 0.588 (0.497, 0.696) ,0.0001 0.641 (0.411, 0.999)* 0.555 (0.438, 0.704)*** 0.606 (0.456, 0.806)**
4 0.610 (0.525, 0.709) ,0.0001 0.623 (0.421, 0.921)* 0.623 (0.504, 0.770)*** 0.576 (0.446, 0.743)***
5 0.668 (0.581, 0.768) ,0.0001 0.691 (0.481, 0.993)* 0.670 (0.551, 0.815)*** 0.639 (0.503, 0.811)**
6 0.703 (0.617, 0.802) ,0.0001 0.727 (0.518, 1.022) 0.692 (0.576, 0.832)*** 0.692 (0.552, 0.867)**
7 0.747 (0.659, 0.848) ,0.0001 0.765 (0.553, 1.059) 0.733 (0.615, 0.875)** 0.743 (0.597, 0.924)*
8 0.773 (0.683, 0.874) ,0.0001 0.774 (0.563, 1.064) 0.756 (0.636, 0.898)** 0.780 (0.630, 0.965)*
9 0.787 (0.698, 0.887) ,0.0001 0.786 (0.576, 1.071) 0.779 (0.660, 0.920)** 0.780 (0.633, 0.959)*
10 0.777 (0.691, 0.874) ,0.0001 0.776 (0.574, 1.051) 0.769 (0.653, 0.904)** 0.773 (0.629, 0.950)*
11 0.788 (0.701, 0.884) ,0.0001 0.789 (0.585, 1.065) 0.776 (0.661, 0.911)** 0.786 (0.641, 0.964)*
12 0.791 (0.705, 0.887) ,0.0001 0.799 (0.593, 1.078) 0.778 (0.664, 0.911)** 0.788 (0.644, 0.964)*
Notes: Data are presented as hazard ratios and 95% confidence intervals. *P,0.05; **P,0.005; ***P,0.0001. BUD/FOr versus FOr.
Abbreviations: exDo, exacerbation and discontinuation; BUD, budesonide; FOr, formoterol.
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The analysis of time-to-first discontinuations showed a 
large difference between active and less active treatment in 
study durations of 2–4 months (~35%). Thereafter, the differ-
ence between treatments for all patients, moderate and severe 
COPD decreased with longer study durations (15%–20% 
for studies $9 months), indicating a decrease in differential 
dropout over time. The very severe COPD group showed a 
different pattern with a high difference between treatments, 
irrespective of study duration (38%–34%). These analyses 
support the CPDo data that the differential dropout effects 
appear early and before the change of treatment differences 
in exacerbations are noted. In addition, and in line with 
CPDo, the impact is more pronounced and longer lasting in 
very severe COPD.
This post hoc analysis has some limitations. Patient 
numbers across the three severity groups comprised a 
skewed distribution, due to the original studies not being 
designed around severities; the limited number of patients 
in the moderate COPD group (n=408) may have affected 
analysis, especially when compared to the severe COPD 
group (n=1,325); patients included in the original trials had a 
history of $1 COPD exacerbation in the previous year so our 
results are not generalizable to all patients with COPD. The 
present analysis only investigated the addition of budesonide 
to formoterol, and our results should, therefore, be validated 
with other drug classes. Finally, analyses such as the one 
presented cannot be generalized to differential dropout due 
to differences in side-effect profiles.
In conclusion, our data indicate that the relative 
treatment differences in exacerbation rates over a whole 
study can vary by threefold. As the benefit of an effective 
intervention may be underestimated in longer studies, 
this may have implications for drug development. Our 
data highlight the importance of study design, patient 
selection, and study duration, and show that subtle differ-
ences in these parameters can make comparisons between 
studies challenging and questionable. Future studies of 
new agents designed to modify exacerbation outcomes 
in COPD may benefit from adopting a shorter focused 
design, which minimizes the effect of differential drop-
out, an approach already shown to be effective in clinical 
trials of COPD.16
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Supplementary materials
Table S1 annualized exacerbation rates for budesonide/formoterol and formoterol for all patients
Study month Annualized exacerbation rates
All patients, n=2,345
BUD/FOR 95% CI FOR 95% CI
1 0.60 0.48–0.84 1.20 0.96–1.44
2 0.60 0.54–0.72 1.20 1.02–1.32
3 0.60 0.52–0.72 1.12 1.0–1.24
4 0.60 0.54–0.69 1.11 0.99–1.23
5 0.62 0.58–0.72 1.06 0.98–1.17
6 0.66 0.60–0.74 1.04 0.96–1.14
7 0.67 0.62–0.74 0.99 0.99–1.06
8 0.68 0.62–0.74 0.95 0.87–1.02
9 0.68 0.63–0.74 0.93 0.93–1.01
10 0.66 0.61–0.72 0.94 0.86–.996
11 0.65 0.61–0.72 0.91 0.85–0.98
12 0.63 0.58–0.68 0.86 0.80–0.92
Abbreviations: BUD, budesonide; CI, confidential interval; FOR, formoterol.
Table S2 exacerbation rate ratios for budesonide/formoterol compared with formoterol in all patients and in the three COPD disease 
severity groups
Study 
month
Exacerbation rate ratios
All patients, n=2,345 Disease severity
Moderate COPD, n=408 Severe COPD, n=1,325 Very severe COPD, n=612
P-value P-value P-value P-value
1 -0.48 (-0.62, -0.29) ,0.0001 -0.50 (-0.80, 0.22) 0.1266 -0.48 (-0.67, -0.19) 0.0036 -0.47 (-0.68, -0.11) 0.0152
2 -0.48 (-0.58, -0.35) ,0.0001 -0.39 (-0.68, 0.15) 0.1270 -0.51 (-0.64, -0.32) ,0.0001 -0.48 (-0.64, -0.25) 0.0004
3 -0.46 (-0.55, -0.35) ,0.0001 -0.45 (-0.67, -0.08) 0.0231 -0.49 (-0.61, -0.34) ,0.0001 -0.41 (-0.57, -0.20) 0.0008
4 -0.45 (-0.53, -0.35) ,0.0001 -0.45 (-0.65, -0.14) 0.0091 -0.45 (-0.56, -0.31) ,0.0001 -0.45 (-0.58, -0.28) ,0.0001
5 -0.40 (-0.48, -0.31) ,0.0001 -0.48 (-0.66, -0.21) 0.0021 -0.40 (-0.51, -0.26) ,0.0001 -0.39 (-0.53, -0.22) ,0.0001
6 -0.36 (-0.44, -0.27) ,0.0001 -0.42 (-0.60, -0.15) 0.0055 -0.37 (-0.48, -0.25) ,0.0001 -0.33 (-0.46, -0.16) 0.0004
7 -0.32 (-0.40, -0.23) ,0.0001 -0.41 (-0.59, -0.15) 0.0043 -0.34 (-0.44, -0.21) ,0.0001 -0.27 (-0.41, -0.10) 0.0037
8 -0.29 (-0.37, -0.20) ,0.0001 -0.39 (-0.57, -0.14) 0.0055 -0.31 (-0.42, -0.19) ,0.0001 -0.23 (-0.37, -0.06) 0.0121
9 -0.28 (-0.36, -0.19) ,0.0001 -0.39 (-0.57, -0.14) 0.0045 -0.30 (-0.40, -0.18) ,0.0001 -0.22 (-0.36, -0.05) 0.0145
10 -0.29 (-0.36, -0.20) ,0.0001 -0.44 (-0.59, -0.21) 0.0007 -0.30 (-0.40, -0.18) ,0.0001 -0.23 (-0.36, -0.06) 0.0082
11 -0.28 (-0.35, -0.19) ,0.0001 -0.42 (-0.58, -0.20) 0.0009 -0.28 (-0.38, -0.17) ,0.0001 -0.23 (-0.36, -0.08) 0.0052
12 -0.27 (-0.35, -0.19) ,0.0001 -0.39 (-0.56, -0.17) 0.0017 -0.29 (-0.38, -0.18) ,0.0001 -0.22 (-0.35, -0.07) 0.0063
Note: Data are presented as reduction in the exacerbation rate ratio and 95% confidence intervals.
Table S3 Time-to-first exacerbation for budesonide/formoterol and formoterol in all patients and according to COPD disease 
severity group
Study 
month
Time-to-first exacerbation
All patients, n=2,345 Disease severity
P-value Moderate COPD, n=408 Severe COPD, n=1,325 Very severe COPD, n=612
1 0.528 (0.385, 0.723) ,0.0001 0.513 (0.207, 1.272) 0.531 (0.340, 0.830)* 0.525 (0.316, 0.873)*
2 0.532 (0.420, 0.673) ,0.0001 0.601 (0.303, 1.194) 0.519 (0.373, 0.722)*** 0.519 (0.352, 0.765)**
3 0.586 (0.478, 0.718) ,0.0001 0.615 (0.347, 1.089) 0.547 (0.412, 0.726)*** 0.625 (0.443, 0.881)*
4 0.599 (0.499, 0.719) ,0.0001 0.578 (0.349, 0.957)* 0.613 (0.476, 0.790)** 0.575 (0.422, 0.782)**
5 0.639 (0.540, 0.758) ,0.0001 0.603 (0.374, 0.974)* 0.641 (0.508, 0.810)** 0.632 (0.474, 0.843)**
6 0.687 (0.586, 0.805) ,0.0001 0.694 (0.447, 1.077) 0.660 (0.531, 0.822)** 0.705 (0.539, 0.923)*
7 0.736 (0.632, 0.857) ,0.0001 0.740 (0.483, 1.134) 0.699 (0.567, 0.862)** 0.770 (0.593, 0.998)*
8 0.772 (0.665, 0.895) 0.0006 0.767 (0.504, 1.165) 0.736 (0.600, 0.903)** 0.806 (0.625, 1.040)
9 0.794 (0.688, 0.917) 0.0017 0.777 (0.516, 1.170) 0.769 (0.632, 0.935)** 0.816 (0.637, 1.046)
10 0.778 (0.676, 0.897) 0.0005 0.710 (0.475, 1.061) 0.754 (0.622, 0.913)** 0.823 (0.643, 1.053)
11 0.788 (0.685, 0.906) 0.0008 0.745 (0.501, 1.107) 0.763 (0.632, 0.921)** 0.823 (0.644, 1.051)
12 0.790 (0.688, 0.907) 0.0008 0.745 (0.501, 1.107) 0.765 (0.635, 0.921)** 0.824 (0.646, 1.050)
Notes: Data are presented as reduction in time-to-first exacerbation and 95% confidence intervals. *P,0.05; **P,0.005; ***P,0.0001. 
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Table S4 Time-to-discontinuations for budesonide/formoterol versus formoterol in all patients and according to COPD disease 
severity group
Study 
month
Time-to-discontinuations
All patients n=2,345 Disease severity
P-value Moderate COPD, n=408 Severe COPD, n=1,325 Very severe COPD, n=612
1 0.998 (0.519, 1.919) 0.9961 0.350 (0.036, 3.369) 1.192 (0.494, 2.876) 1.000 (0.323, 3.101)
2 0.709 (0.503, 0.999) 0.0494 0.791 (0.274, 2.280) 0.695 (0.428, 1.130) 0.700 (0.406, 1.210)
3 0.651 (0.500, 0.846) 0.0013 0.684 (0.357, 1.312) 0.660 (0.454, 0.961)* 0.623 (0.400, 0.972)*
4 0.665 (0.529, 0.836) 0.0005 0.673 (0.383, 1.180) 0.692 (0.497, 0.965)* 0.627 (0.427, 0.921)*
5 0.724 (0.587, 0.892) 0.0024 0.838 (0.514, 1.366) 0.737 (0.545, 0.997)* 0.655 (0.457, 0.939)*
6 0.695 (0.571, 0.847) 0.0003 0.723 (0.454, 1.153) 0.737 (0.556, 0.977)* 0.625 (0.443, 0.882)*
7 0.723 (0.600, 0.871) 0.0007 0.716 (0.463, 1.110) 0.798 (0.611, 1.042) 0.631 (0.456, 0.873)*
8 0.728 (0.609, 0.870) 0.0005 0.752 (0.495, 1.142) 0.788 (0.608, 1.020) 0.639 (0.472, 0.867)**
9 0.735 (0.619, 0.874) 0.0005 0.762 (0.506, 1.147) 0.802 (0.623, 1.031) 0.637 (0.475, 0.855)**
10 0.750 (0.633, 0.887) 0.0008 0.775 (0.521, 1.151) 0.834 (0.654, 1.064) 0.629 (0.471, 0.840)**
11 0.761 (0.646, 0.896) 0.0010 0.815 (0.553, 1.200) 0.822 (0.649, 1.041) 0.652 (0.493, 0.863)**
12 0.779 (0.663, 0.915) 0.0023 0.850 (0.580, 1.246) 0.849 (0.673, 1.071) 0.652 (0.496, 0.857)**
Notes: Data are presented as hazard ratios and 95% confidence intervals. *P,0.05; **P,0.005.
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Figure S1 exacerbation rate for budesonide/formoterol and formoterol over time according to COPD disease severity: (A) moderate COPD, (B) severe COPD, and 
(C) very severe COPD.
Note: Data are presented as 95% confidence intervals.
Abbreviations: BUD, budesonide; FOrM, formoterol.
